Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMMX
SellHot AirImmix Biopharma, Inc. · Healthcare · United States · $992M · Avg Vol: $19M/d
COMPANY DESCRIPTION
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing novel anti-cancer therapies based on its proprietary SMARxT Tissue-Specific™ Platform. The company focuses on developing tissue-specific therapeutics designed to enhance efficacy and reduce side effects by concentrating drugs in tumor tissues. Its innovative approach aims to address high unmet medical needs in oncology, differentiating it within the competitive cancer therapy landscape.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 15.2M | — |
| EPS | — | -0.12 | -0.25 | -0.29 | -0.89 | — | -0.88 | -0.75 | -0.91 | — |
| Shares | — | 71.2M | 71.2M | 71.2M | 53.0M | -25.6% | 71.2M | — | — | — |
| Debt | 50.0K | — | 0 | 1.1M | 1.1M | 115.2% | 1.0M | — | — | — |
| Equity | — | 13.2M | 16.4M | 13.3M | 93.8M | 92.4% | — | — | — | — |
| Op CF | — | -7.4M | -11.4M | -14.6M | -23.9M | — | -38.5M | — | — | — |
| Inv CF | — | 0 | -52.1K | -1.2M | -7.2M | — | — | — | — | — |
| Fin CF | — | 3.2M | 15.5M | 15.9M | 107.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMMX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc.(you) | $992M | 28 | Sell |
| CADL | Candel Therapeutics, Inc. | $1.0B | 26 | Sell |
| LXRX | Lexicon Pharmaceuticals, Inc. | $1.0B | 26 | Sell |
| DSGN | Design Therapeutics, Inc. | $946M | 30 | Sell |
| JANX | Janux Therapeutics, Inc. | $1.1B | 27 | Sell |
| SLDB | Solid Biosciences Inc. | $1.0B | 32 | Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 24 | Sell |
| ACRS | Aclaris Therapeutics, Inc. | $885M | 24 | Sell |
| APMD | Apnimed, Inc. | $1.2B | 32 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%